What Has Been the Growth Trajectory for the C-Reactive Protein Testing Market in Recent Years?
The c-reactive protein testing market has seen considerable growth due to a variety of factors.
• In the past few years, the market size for c-reactive protein testing has been on a steady rise. Its value is projected to increase from $3.45 billion in 2024 to $3.55 billion in 2025, reflecting a compound annual growth rate (CAGR) of 2.9%.
Factors such as the rise in the incidence of inflammatory diseases, assessments of cardiovascular risk, the ageing population, enhanced healthcare infrastructure and medical screening initiatives have contributed to the growth observed during the historical period.
How Does the Forecast Look for the C-Reactive Protein Testing Market?
The c-reactive protein testing market is expected to maintain its strong growth trajectory in upcoming years.
• The market for c-reactive protein testing is projected to experience robust expansion in the coming years, reaching $4.35 billion in 2029 with a compound annual growth rate (CAGR) of 5.2%.
The anticipated growth during this forecast period can be linked to factors such as increasing obesity rates, the incorporation of personalized medicine and biomarkers, the adoption of telehealth and remote monitoring, early detection of diseases, and inflammation associated with lifestyle choices. Key trends to watch out for during this period encompass advancements in diagnostic testing, the proliferation of wearable health devices, technological innovations, strategic partnerships, and the entry of industry 4.0.
What Are the Critical Driver Fuelling the C-Reactive Protein Testing Market's Growth?
Cardiovascular diseases (CVD), which include conditions like diseased vessels, structural issues, and blood clots, have seen a spike in occurrences, anticipated to fuel the development of the c-reactive protein testing market. The exact origins of CVD remain unknown, but several contributing factors increase the likelihood of its development. These include behavior-based risks such as poor diet, physical inactivity, smoking, and alcohol consumption, all of which result in the buildup of fatty deposits in the arteries (atherosclerosis) thereby increasing the risk of blood clot formation. These lifestyle choices can result in increased blood pressure, blood sugar, blood lipids, weight gain, and obesity. The surge in CVD cases necessitates the use of c-reactive protein testing to identify or assess the potential for cardiovascular complications, equally or more effectively than cholesterol level determination. As per data from the Institute for Health Metrics and Evaluation in December 2023, global deaths from cardiovascular diseases (CVDs) were around 19.8 million in 2022, primarily due to ischemic heart disease with a rate of 108.8 deaths per 100,000 people. High systolic blood pressure was the chief cause of disability-adjusted life years (DALYs) associated with CVD, whereas dietary habits and air pollution were the major behavioral and environmental contributors to this worldwide issue.
How Is the C-Reactive Protein Testing Market segmented?
The c-reactive protein testing market covered in this report is segmented –
1) By Assay Type: Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunoturbidimetric Assays
2) By Application: Diabetes, Rheumatoid Arthritis, Cardiovascular Disease, Inflammatory Bowel Disease, Cancer, Other Applications
3) By End Use: Clinics, Hospitals, Diagnostic Laboratories
Subsegments:
1) By Enzyme-Linked Immunosorbent Assay (ELISA): Direct ELISA, Indirect ELISA, Sandwich ELISA
2) By Chemiluminescence Immunoassay (CLIA): Luminometer-Based CLIA, Automated CLIA Systems
3) By Immunoturbidimetric Assays: Nephelometry-Based Immunoturbidimetric Assays, Latex Agglutination Immunoturbidimetric Assays
Pre-Book The C-Reactive Protein Testing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing the C-Reactive Protein Testing Market?
The c-reactive protein testing market is witnessing a key trend where significant technological advancements in measuring devices are prevalent. To fortify their market stance, major businesses in this market are concentrating on providing solutions employing advanced technology. They are incorporating cutting-edge c-reactive testing methodologies and innovative solutions promising high output and versatile applications. For instance, in February 2022, Aidian, a company predicated in Finland providing diagnostic tests and testing solutions, launched its QuikRead go wrCRP & wrCRP+Hb kits. This kit allows for simultaneous production of two results, a wide spectrum of CRP and Hb, using a single sample and analysis. This wide-range CRP test assists in evaluating conditions like neonatal sepsis, predicting the severity of diseases like COPD (chronic obstructive pulmonary disease), and in cardiovascular risk assessment.
Who Are the Key Players in the C-Reactive Protein Testing Market?
Major companies operating in the c-reactive protein testing market include:
• Thermo Fisher Scientific Inc.
• F Hoffmann-La Roche AG
• Danaher Corporation
• Quest Diagnostics Incorporated
• Siemens AG
• Abbott Laboratories
• Aidian Oy
• Boditech Med Inc.
• Horiba Ltd.
• Laboratory Corporation
• Merck KGAA
• Randox Laboratories Limited
• Getein Biotech Inc.
• Bio-Rad Laboratories Inc.
• DiaSorin S.p.A.
• Eurofins Scientific SE
• Inova Diagnostics Inc.
• Luminex Corporation
• Sekisui Diagnostics LLC
• Sysmex Corporation
• Tosoh Corporation
• Trinity Biotech Plc
• WerfenLife Group LLC
• ZEUS Scientific Inc.
• BioMérieux SA
• Biomerica Inc.
• Gold Standard Diagnostics Corp.
• Immunodiagnostic Systems Holdings PLC
• Nova Biomedical Corporation
What Is The Most Dominant Region In The C-Reactive Protein Testing Market?
North America was the largest region in the c-reactive protein testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the c-reactive protein testing market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
